Your browser is no longer supported. Please, upgrade your browser.
Settings
APTO Aptose Biosciences Inc. daily Stock Chart
APTO [NASD]
Aptose Biosciences Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own20.40% Shs Outstand71.14M Perf Week14.97%
Market Cap426.13M Forward P/E- EPS next Y-0.57 Insider Trans0.09% Shs Float70.63M Perf Month-22.21%
Income-26.30M PEG- EPS next Q-0.10 Inst Own35.10% Short Float0.55% Perf Quarter6.96%
Sales- P/S- EPS this Y39.40% Inst Trans1.01% Short Ratio0.35 Perf Half Y153.81%
Book/sh1.60 P/B3.74 EPS next Y22.20% ROA-55.10% Target Price4.89 Perf Year202.53%
Cash/sh1.37 P/C4.37 EPS next 5Y- ROE-61.60% 52W Range1.81 - 9.25 Perf YTD5.64%
Dividend- P/FCF- EPS past 5Y4.80% ROI- 52W High-35.26% Beta1.85
Dividend %- Quick Ratio17.80 Sales past 5Y- Gross Margin- 52W Low230.94% ATR0.75
Employees31 Current Ratio17.80 Sales Q/Q- Oper. Margin- RSI (14)47.15 Volatility9.11% 13.23%
OptionableYes Debt/Eq0.02 EPS Q/Q21.50% Profit Margin- Rel Volume0.64 Prev Close6.16
ShortableYes LT Debt/Eq0.01 EarningsMar 10 AMC Payout- Avg Volume1.11M Price5.99
Recom2.00 SMA20-5.97% SMA50-12.45% SMA20055.75% Volume713,154 Change-2.76%
Feb-20-20Initiated Maxim Group Buy $16
Feb-06-20Reiterated H.C. Wainwright Buy $6 → $9
Jan-09-20Initiated Piper Sandler Overweight $10
Mar-01-19Initiated RBC Capital Mkts Outperform $6
Nov-16-18Initiated B. Riley FBR Buy $5
Dec-13-17Reiterated H.C. Wainwright Buy
Oct-23-17Resumed ROTH Capital Buy $5
Sep-07-17Upgrade H.C. Wainwright Neutral → Buy $1 → $4
Jun-08-17Initiated Rodman & Renshaw Neutral $1
Mar-10-20 04:02PM  Aptose Reports Results for the Fourth Quarter and Full Year 2019 GlobeNewswire
03:00PM  Aptose Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-25-20 07:31AM  Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020 GlobeNewswire
Feb-21-20 08:35AM  Are Options Traders Betting on a Big Move in Aptose (APTO) Stock? Zacks
Feb-05-20 11:52AM  Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-29-20 07:30AM  Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference GlobeNewswire +6.62%
07:01AM  Top Ranked Momentum Stocks to Buy for January 29th Zacks
Jan-28-20 02:36PM  5 'Strong Buy' Biotech Stocks to Buy for 2020 Kiplinger +6.71%
Jan-17-20 08:44AM  Is the Options Market Predicting a Spike in Aptose (APTO) Stock? Zacks
Jan-07-20 07:30AM  Aptose Biosciences to Present at Biotech Showcase 2020 Conference GlobeNewswire
Dec-19-19 04:02PM  Aptose Announces Closing of Public Offering of Common Shares GlobeNewswire +6.96%
03:50PM  Hedge Funds Have Never Been This Bullish On Aptose Biosciences Inc (APTO) Insider Monkey
Dec-17-19 08:00AM  Aptose Announces Pricing of Public Offering of Common Shares GlobeNewswire -8.13%
07:56AM  The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO Benzinga
Dec-16-19 04:19PM  Aptose Announces Proposed Public Offering of Common Shares GlobeNewswire +8.98%
Dec-09-19 11:00AM  Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting GlobeNewswire +38.28%
Dec-07-19 11:00AM  Aptose Presents Highlights From Corporate Event At ASH GlobeNewswire
Dec-04-19 07:30AM  Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer GlobeNewswire
Dec-02-19 07:30AM  Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire -5.17%
Nov-11-19 08:26AM  Is Aptose Biosciences (TSE:APS) In A Good Position To Deliver On Growth Plans? Simply Wall St. +8.23%
Nov-07-19 07:30AM  Aptose to Present at BIO-Europe Conference GlobeNewswire
Nov-06-19 09:54AM  Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting GlobeNewswire
Nov-05-19 04:02PM  Aptose Reports Results for the Third Quarter Ended September 30, 2019 GlobeNewswire
Oct-22-19 07:00AM  Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019 GlobeNewswire
Oct-10-19 07:30AM  Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH) GlobeNewswire
Sep-16-19 07:30AM  Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies GlobeNewswire -5.38%
Sep-12-19 06:46AM  How Much Are Aptose Biosciences Inc. (TSE:APS) Insiders Spending On Buying Shares? Simply Wall St.
Aug-06-19 04:00PM  Aptose Reports Results for the Second Quarter Ended June 30, 2019 GlobeNewswire
Jul-30-19 07:30AM  Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
Jul-23-19 07:30AM  Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019 GlobeNewswire
Jul-16-19 07:05AM  Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253 GlobeNewswire
Jul-08-19 10:24AM  The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu Zacks
Jul-05-19 08:38AM  Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks Zacks +7.12%
Jun-14-19 07:00AM  Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association GlobeNewswire
Jun-04-19 04:02PM  Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders GlobeNewswire
Jun-03-19 09:00AM  Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer GlobeNewswire
08:38AM  Aptose Announces Closing of Public Offering of Common Shares GlobeNewswire
May-31-19 08:00AM  Aptose to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-30-19 09:01AM  Aptose Announces Pricing of Public Offering of Common Shares GlobeNewswire -11.11%
May-29-19 04:22PM  Aptose Announces Proposed Public Offering of Common Shares GlobeNewswire +11.94%
May-24-19 05:43PM  Aptose Biosciences Establishes New At-The-Market Facility GlobeNewswire
May-16-19 10:02AM  Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association GlobeNewswire
May-13-19 08:15AM  Aptose to Present at May Investor Conferences GlobeNewswire -6.88%
May-10-19 07:24PM  Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC GlobeNewswire
May-07-19 05:25PM  Aptose Biosciences: 1Q Earnings Snapshot Associated Press
04:01PM  Aptose Reports Results for the First Quarter Ended March 31, 2019 GlobeNewswire
Apr-24-19 07:30AM  Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019 GlobeNewswire
Apr-23-19 07:30AM  Aptose To Release First Quarter Ended March 31, 2019 Financial Results and Hold Conference Call on May 7, 2019 GlobeNewswire
Apr-02-19 07:00AM  Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-25-19 07:02AM  Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806 GlobeNewswire
Mar-12-19 05:18PM  Aptose Biosciences: 4Q Earnings Snapshot Associated Press +5.45%
04:02PM  Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018 GlobeNewswire
Mar-07-19 07:00AM  Aptose to Participate in Upcoming Investor Conferences in March 2019 GlobeNewswire
Mar-04-19 07:00AM  Aptose Biosciences and CrystalGenomics Announce Issuance of Australian Patent for CG-806 GlobeNewswire -5.03%
Feb-28-19 07:00AM  Aptose to Present New CG-806 and APTO-253 Data at the 2019 AACR Annual Meeting GlobeNewswire
Feb-26-19 07:30AM  Aptose To Release Fourth Quarter and Year End December 31, 2018 Financial Results and Hold Conference Call on March 12, 2019 GlobeNewswire
Feb-25-19 07:00AM  Aptose Biosciences Submits IND Application for CG-806 GlobeNewswire -5.02%
Feb-21-19 08:55AM  Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings? Zacks
Feb-20-19 08:54AM  Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings? Zacks
Feb-19-19 07:30AM  Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-02-19 07:25AM  Factors of Influence in 2019, Key Indicators and Opportunity within The TJX Companies, Nasdaq, Werner Enterprises, Global Ship Lease, Domo, and Aptose Biosciences New Research Emphasizes Economic Growth GlobeNewswire +15.18%
07:05AM  Aptose Biosciences to Present at Biotech Showcase 2019 Conference GlobeNewswire
Dec-24-18 06:12AM  Aptose Biosciences Sees Hammer Chart Pattern: Time to Buy? Zacks -7.07%
Dec-12-18 10:00AM  Aptose Presents Highlights From CG-806 KOL Event GlobeNewswire +9.09%
Dec-03-18 07:10AM  OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting GlobeNewswire
07:05AM  Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting GlobeNewswire
Nov-26-18 07:05AM  Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies GlobeNewswire
Nov-20-18 07:05AM  Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting GlobeNewswire
Nov-14-18 08:40AM  New Research: Key Drivers of Growth for WellCare Health Plans, Streamline Health Solutions, Aptose Biosciences, Houston Wire & Cable, RTI Surgical, and Atlantica Yield Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-06-18 05:58PM  Aptose Biosciences: 3Q Earnings Snapshot Associated Press
04:05PM  Aptose Reports Results for the Third Quarter Ended September 30, 2018 GlobeNewswire
Nov-01-18 09:26AM  Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting GlobeNewswire +17.97%
Oct-23-18 07:05AM  Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018 GlobeNewswire
Sep-27-18 07:05AM  Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806 GlobeNewswire
Sep-25-18 07:05AM  Aptose to Present at Upcoming Investor Conferences in October 2018 GlobeNewswire
Aug-29-18 07:05AM  Aptose to Present at Upcoming Investor Conferences in September 2018 GlobeNewswire
Aug-15-18 07:05AM  Aptose Announces Appointment of Carol Ashe to Board of Directors GlobeNewswire -6.85%
Aug-08-18 05:05AM  Aptose Biosciences: 2Q Earnings Snapshot Associated Press
Aug-07-18 04:18PM  Aptose Reports Results for the Second Quarter Ended June 30, 2018 GlobeNewswire
01:22PM  Breaking Down Aptose Biosciences Incs (TSE:APS) Ownership Structure Simply Wall St.
Aug-02-18 07:05AM  Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-31-18 08:00AM  Aptose to Present at the 2018 Global Congress on Oncology and Cancer GlobeNewswire +5.54%
Jul-27-18 08:56AM  New Strong Sell Stocks for July 27th Zacks
Jul-24-18 07:05AM  Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018 GlobeNewswire
Jul-23-18 05:56AM  New Strong Sell Stocks for July 23rd Zacks
Jul-11-18 08:30AM  Why Aptose Biosciences (APTO) Could Be Positioned for a Slump Zacks -6.71%
Jul-10-18 08:13AM  New Strong Sell Stocks for July 10th Zacks
07:00AM  Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806 GlobeNewswire
Jul-09-18 07:00AM  Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day GlobeNewswire
Jun-29-18 09:00AM  Penny Stocks to Buy Using Technical Analysis Investopedia
07:00AM  FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers GlobeNewswire
Jun-15-18 08:00AM  Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association GlobeNewswire +6.94%
Jun-14-18 07:01PM  Aptose Biosciences Incs (TSE:APS) Profit Outlook Simply Wall St.
08:55AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:05AM  Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China GlobeNewswire
Jun-05-18 04:05PM  Aptose Biosciences Announces Results of Annual Meeting of Shareholders GlobeNewswire
Jun-04-18 07:04AM  Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 GlobeNewswire
May-31-18 07:04AM  APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC GlobeNewswire
May-17-18 11:43AM  Aptose to Present New CG806 Data at the 23rd Congress of the European Hematology Association GlobeNewswire
May-10-18 04:41PM  Aptose Biosciences: 1Q Earnings Snapshot Associated Press
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rice William G.Chair, President & CEOMar 25Buy5.823,40019,803466,414Mar 26 01:10 PM
Rice William G.Chairman, President & CEOOct 24Buy1.9210,00019,200163,014Oct 28 01:59 PM
Chow Gregory K.Senior VP & CFOJun 05Buy1.847,50013,815134,514Jun 07 02:03 PM
Rice William G.Chair, President & CEOApr 18Buy1.8510,00018,507153,014Apr 19 02:35 PM